Research programme: drug and vaccine therapeutics - Pharmsynthez/Xenetic Biosciences

Drug Profile

Research programme: drug and vaccine therapeutics - Pharmsynthez/Xenetic Biosciences

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lipoxen Technologies; Pharmsynthez
  • Developer Pharmsynthez; Xenetic Biosciences
  • Class Cancer vaccines; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cystic fibrosis; HIV infections; Multiple sclerosis; Non-Hodgkin's lymphoma; Type 2 diabetes mellitus

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 12 May 2014 Preclinical development is ongoing
  • 08 Sep 2011 Lipoxen is now called Xenetic Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top